Skip to Main Content

Paper Details

High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma.
Blood
17
2023
HDM, MM, RVD, bortezomib, dexamethasone, double, lenalidomide, melphalan, multiple myeloma, myeloma, myeloma cells, patients, transcribed strand
Author NameAffiliation
Marco RoncadorZurich University Hospital
Giovanni ParmigianiDana-Farber Cancer Institute
Giovanni ParmigianiHarvard T.H. Chan School of Public Health, Harvard University
Giovanni ParmigianiDana-Farber Cancer Institute
Giovanni ParmigianiHarvard T.H. Chan School of Public Health, Harvard University
Kenneth C AndersonDana-Farber Cancer Institute, Harvard Medical School, Harvard University
Kenneth C AndersonDana-Farber Cancer Institute, Harvard Medical School, Harvard University
  • 1 - 7

Datasets

Release 1.2